Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal guidance
  • TA175
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 374.